Drug Trial Radar · NCT00987844
Study to Evaluate Long-Term Safety, Tolerability, and Satisfaction With Prucalopride in Chronic Constipation
Last checked: Nov 20, 2026Latest source record: Oct 1, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,775
Actual
Start
Jul 1998
Primary completion
Nov 2000
Sponsor
- Lead sponsor
- MovetisIndustry
- Sponsor type
- Industry
- First posted
- Oct 1, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Objectives: To evaluate the clinical long-term safety and the tolerability, patient satisfaction, pharmacokinetics and use of pattern of prucalopride given in doses up to 4 mg per day to patients with chronic constipation (CC).
Conditions
- Chronic Constipation
Interventions
PrucaloprideDrug
1 mg tablets, free dosing regiment with max. of 4 tablets o.d., treatment duration: up to 24 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: adverse events, lab tests, vital signs, ECGsTime frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mayo Clinic
Rochester, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.